SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NCT03113643 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome
Blastic Plasmacytoid Dendritic Cell Neoplasm

Interventions

DRUG: Azacitidine
DRUG: SL-401
DRUG: Venetoclax

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]